Baptist Memorial Hospital
Baptist Memorial Hospital was paid $51.45M by Medicaid between Jan 2018 and Dec 2024, across 169 billing codes. Its largest line is 99284, emergency room visit (serious) — 28% of everything it billed.
MEMPHIS, TN 38120
Next to other Multi-Specialty Clinic/Center providers in Tennessee
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 224,243 | $9.10M | |
| 2019 | 194,651 | $6.95M | |
| 2020 | 150,877 | $5.18M | |
| 2021 | 170,638 | $6.24M | |
| 2022 | 221,646 | $8.23M | |
| 2023 | 244,570 | $9.05M | |
| 2024incomplete | 156,918 | $6.70M |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 28% | 87,850 | 77,679 | $14.25M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 21% | 93,687 | 87,874 | $10.89M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 16% | 40,740 | 33,455 | $8.45M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.9% | 28,094 | 27,317 | $1.99M |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 3.2% | 39,348 | 35,956 | $1.66M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.7% | 32,791 | 27,419 | $1.37M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.7% | 2,879 | 2,425 | $1.37M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.9% | 21,369 | 20,148 | $986K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.9% | 113,607 | 54,415 | $956K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.3% | 54,546 | 49,778 | $692K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.2% | 12,159 | 11,840 | $633K |
| G0378 | Hospital observation service, per hour | 1.1% | 5,313 | 2,266 | $580K |
157 more codes
| 84484 | 1.1% | 38,244 | $574K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 14,756 | $512K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 21,071 | $507K |
| 80053 | Comprehensive metabolic panel | <1% | 101,639 | $503K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 80,996 | $488K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 20,777 | $367K |
| 71045 | Radiologic examination, chest; single view | <1% | 25,882 | $355K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 51,749 | $331K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 10,274 | $280K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 2,403 | $274K |
| 43775 | <1% | 179 | $254K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 1,722 | $222K |
| 36415 | Collection of venous blood by venipuncture | <1% | 124,612 | $220K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 6,598 | $180K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 3,320 | $177K |
| 87807 | <1% | 16,717 | $171K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,944 | $171K |
| 84703 | <1% | 22,268 | $165K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,962 | $143K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 9,549 | $113K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 9,955 | $105K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,490 | $101K |
| 83735 | <1% | 18,172 | $80K | |
| 85027 | <1% | 20,590 | $79K | |
| 92587 | <1% | 1,892 | $77K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 5,335 | $76K |
| 92651 | <1% | 973 | $75K | |
| 83690 | <1% | 11,791 | $70K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 785 | $67K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 158 | $57K |
| 58662 | <1% | 64 | $52K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 636 | $51K |
| 81001 | <1% | 40,098 | $50K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 12,074 | $43K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 95 | $43K |
| 58571 | <1% | 43 | $41K | |
| 74246 | <1% | 616 | $33K | |
| 83880 | <1% | 2,464 | $32K | |
| 86900 | <1% | 1,594 | $30K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,973 | $29K |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 2,819 | $25K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 599 | $24K |
| 92586 | <1% | 310 | $24K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 7,107 | $24K |
| 36821 | <1% | 46 | $21K | |
| 83605 | <1% | 2,116 | $18K | |
| 81025 | <1% | 4,383 | $18K | |
| 86850 | <1% | 1,505 | $16K | |
| 92585 | <1% | 308 | $15K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 29 | $15K |
| 85610 | <1% | 5,290 | $13K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 204 | $12K |
| 81003 | <1% | 9,268 | $12K | |
| 85730 | <1% | 2,027 | $11K | |
| 86901 | <1% | 1,629 | $11K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 485 | $11K |
| 0001A | <1% | 382 | $10K | |
| 0002A | <1% | 323 | $9K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 996 | $8K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 305 | $8K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 141 | $8K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 818 | $7K |
| 73130 | <1% | 523 | $6K | |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | <1% | 13 | $6K |
| 84702 | <1% | 396 | $6K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 178 | $5K |
| 77336 | <1% | 80 | $5K | |
| 74019 | <1% | 471 | $5K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 9,825 | $4K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 8,012 | $4K |
| 76830 | Ultrasound, transvaginal | <1% | 58 | $4K |
| 73560 | <1% | 331 | $4K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 8,689 | $4K |
| 86140 | <1% | 555 | $3K | |
| 85379 | <1% | 271 | $3K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 13 | $2K |
| 80074 | <1% | 545 | $2K | |
| 76801 | <1% | 28 | $2K | |
| 82550 | <1% | 380 | $2K | |
| 73630 | <1% | 188 | $2K | |
| 83874 | <1% | 156 | $2K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 618 | $1K |
| 72170 | <1% | 104 | $1K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 26 | $1K |
| 82150 | <1% | 194 | $1K | |
| 74018 | <1% | 145 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 11,341 | $1K |
| 72100 | <1% | 84 | $1K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 41 | $1K |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 462 | $1K |
| 80061 | Lipid panel | <1% | 568 | $985.68 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 37 | $931.70 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 37 | $931.70 |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 25 | $849.30 |
| 93017 | <1% | 15 | $832.11 | |
| J2704 | Injection, propofol, 10 mg | <1% | 11,051 | $830.32 |
| 93312 | <1% | 28 | $822.70 | |
| 84480 | <1% | 551 | $788.26 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,788 | $768.66 |
| 87040 | <1% | 123 | $764.49 | |
| A9270 | Non-covered item or service | <1% | 8,129 | $728.79 |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 13 | $683.18 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 118 | $642.54 |
| 0012A | <1% | 31 | $567.14 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 4,922 | $563.10 |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 12 | $562.72 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 159 | $474.50 |
| C1769 | Guide wire | <1% | 111 | $465.82 |
| 86702 | <1% | 158 | $452.71 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 325 | $426.36 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 520 | $421.60 |
| 93750 | <1% | 15 | $381.55 | |
| 84436 | <1% | 546 | $364.90 | |
| 86701 | <1% | 158 | $328.86 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 2,270 | $318.63 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 968 | $304.31 |
| 85007 | <1% | 61 | $298.37 | |
| 97597 | <1% | 27 | $297.20 | |
| 96376 | <1% | 663 | $278.08 | |
| 96367 | <1% | 55 | $275.30 | |
| 82565 | <1% | 79 | $238.26 | |
| 0011A | <1% | 19 | $225.37 | |
| 83540 | <1% | 69 | $224.28 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,147 | $204.69 |
| 83615 | <1% | 191 | $161.13 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,695 | $130.83 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 108 | $111.19 |
| 93320 | <1% | 28 | $106.91 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 139 | $92.27 |
| 87300 | <1% | 29 | $81.52 | |
| G0008 | Administration of influenza virus vaccine | <1% | 24 | $72.02 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,227 | $59.87 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 21 | $58.83 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,670 | $58.56 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 351 | $55.44 |
| 87205 | <1% | 18 | $54.36 | |
| 87210 | <1% | 20 | $51.56 | |
| 92650 | <1% | 36 | $46.84 | |
| 93325 | <1% | 28 | $46.60 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,262 | $43.43 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,203 | $42.20 |
| 88307 | <1% | 124 | $37.62 | |
| 85014 | <1% | 29 | $32.03 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 7,533 | $19.02 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 210 | $13.00 |
| 90686 | <1% | 24 | $8.69 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 15 | $5.18 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 49 | $2.52 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 114 | $0.51 |
| 80197 | 0% | 34 | $0.00 | |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 125 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 69 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 95 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 164 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 351 | $0.00 |
| 91300 | 0% | 82 | $0.00 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.